Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02731235
Other study ID # H-15012371
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date March 2024

Study information

Verified date September 2022
Source Herlev Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In a randomized-controlled study the effect of high-intensity training, 5 days a week at home for 12 weeks is tested in patients with lacunar stroke.


Description:

Little is known about effect of exercise for patients with lacunar stroke, no studies have investigated the feasibility or effect of aerobic exercise in this subgroup of stroke. The patients have few and temporary symptoms and are therefore early discharged from the hospital. After an cerebral infarct the patients have increased risk of recurrent stroke and they are at risk of developing cognitive deficits or vascular dementia over time. Researchers want to investigate if high-intensity training at home in the acute phase has an effect on aerobic fitness, endothelial response and health profile in this potential fragile group of patients. We hope to increase the patients´ physical and mental function, and thereby prevent a recurrent stroke and slow the progression of vascular diseases.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 71
Est. completion date March 2024
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - lacunar stroke verified by clinical examination and CT- or MRI-scans - able to speak and read Danish Exclusion Criteria: - previous large artery stroke, - symptoms or co-morbidities in the musculoskeletal system, which hinder bicycling, - dyspnoea caused by heart or pulmonary disease, - aphasia or dementia which hinder completion of the Talk Test. Amendment 1 (version 4.0, June 2016) has been modified to allow an extended inclusion period from 0-21 days (previously 0-7 days). Also, to allow inclusion of patients with recurrent lacunar stroke, with clinical symptoms and a corresponding ischemic lesion on MRI. Amendment 2 (version 5.0, June 2017) has allowed inclusion from two other stroke units in the Capital Region of Copenhagen due to low recruitment rate. The article describes protocol version 5.0 from June 6th. 2017

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High-intensity training
high intensity training 5 days a week for 12 weeks
Drug:
prophylactic stroke medication
Usual care medication for stroke prophylaxis
Behavioral:
Recommendations for lifestyle changes
Advise on diet, alcohol, smoking and exercise

Locations

Country Name City State
Denmark Herlev Hospital, Dept Neurology Herlev

Sponsors (3)

Lead Sponsor Collaborator
Herlev Hospital Association of Danish Physiotherapists, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Cardio-vascular event or death Follow-up 5 years from inclusion on cardiovascular events or death 5 years
Primary Difference in the 'Graded Cycling Test with Talk Test' Sub-maximal exercise test on a stationary bicycle at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Endothelial response measurement of endothelial response by Endopat2000 at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Physical Activity Scale (PAS) A questionnaire that measures the level of self-reported physical activity at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Short time activity measurements Accelerometer (Axivity) to short time registration of physical activity (24 hours in an 8 day period (after inclusion, before 3 months visit, before 12 month visit) at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary The WHO-five Well-being Index (WHO-5) A questionnaire that measures current mental well-being at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Montreal Cognitive Assessment (MOCA) A cognitive screening test for detection of mild cognitive impairments at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Major Depression Inventory (MDI) A self-report mood questionnaire at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Multidimensional Fatigue Inventory (MFI-20) A 20-item self-report instrument designed to measure fatigue. at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Ull-Meter An instrument which measures the individual stress reaction - it presents an objective number for the body and mind's state of stress. At baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Blood samples Blood samples to determine cardiovascular risk factors at baseline, 3 (primary analysis), 6 and 12 months after baseline testing
Secondary Magnetic resonance Imaging (MRI) Detection of new infarcts or white matter lesions 12 months after baseline testing
See also
  Status Clinical Trial Phase
Completed NCT02801032 - Effect of Tadalafil on Cerebral Large Arteries in Stroke Phase 2
Completed NCT03635177 - Effect of Remote Ischemic Conditioning on Vascular Health in Stroke Patients N/A
Completed NCT03451591 - LACunar Intervention (LACI-2) Trial-2 Phase 2/Phase 3
Completed NCT04770363 - Comparison Between Unihemispheric and Bihemispheric TCDS in Subacute Ischemic Stroke Patients N/A
Terminated NCT04011202 - Virtual Reality, Mood, and Sedentary Behaviour After Stroke N/A
Active, not recruiting NCT05035823 - COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis N/A
Withdrawn NCT05041114 - SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis N/A